Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Bladder Cancer
Interventions
DRUG

Docetaxel

25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.

DRUG

ZD1839

250 mg by mouth daily, without break.

DRUG

Dexamethasone

"Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER